Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBA1
- Development stage
- Preclinical
- Lead developer
- University of Pavia
- Modality
- Small Molecules
01
Overview
RBA1 is a preclinical small-molecule inhibitor of the RNA-binding protein HuR (ELAVL1), developed for the treatment of glioblastoma (GBM) and other resistant cancers, including lung and breast cancers. It is the lead compound of the resorcinol-benzil-amide (RBA) series. HuR acts as a key post-transcriptional regulator that stabilizes messenger RNAs (mRNAs) encoding pro-inflammatory cytokines, inflammatory enzymes, and acute-phase proteins, thereby promoting cancer hallmarks such as proliferation, invasion, metastasis, and apoptosis resistance. By disrupting the HuR-mRNA interaction, RBA1 induces apoptosis and exhibits cytotoxic activity in glioblastoma patient-derived cell lines, as well as lung and breast cancer cell lines.
- Other names
- resorcinol-benzil-amide 1resorcinol-benzil-amide1resorcinol-benzil-amide-1resorcinol-benzil-ammide 1resorcinol-benzil-ammide1resorcinol-benzil-ammide-1
02
Targets
ELAVL1 (Human Antigen R)
Beyond the preview
Go deeper on RBA1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBA1.